Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study

@article{Patterson2007MiglustatFT,
  title={Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study},
  author={Marc C. Patterson and Darleen Vecchio and Helena Prady and Larry A. Abel and James E. Wraith},
  journal={The Lancet Neurology},
  year={2007},
  volume={6},
  pages={765-772}
}

Figures and Tables from this paper

Miglustat: A Review of Its Use in Niemann-Pick Disease Type C

In the absence of a cure, miglustat is a valuable agent to reduce the progression of clinically relevant neurological symptoms in paediatric and adult patients with NP-C, which is considered a significant achievement in the treatment of this disease.

Early miglustat therapy in infantile Niemann-Pick disease type C.

New agents and approaches to treatment in Niemann-Pick type C disease.

The key laboratory diagnostic test for NP-C is filliping staining of cultured skin fibroblasts from the patient, to demonstrate free cholesterol accumulation in lysosomes secondary to impaired intracellular cholesterol transport.

Miglustat in Niemann-Pick disease type C patients: a review

The effects of miglustat on neurological NP-C manifestations has been assessed using a range of approaches, with benefits ranging from cellular changes in the brain through to visible clinical improvements and improved survival.

Current and future therapies for Niemann–Pick C disease

The key laboratory diagnostic test for NPC is filipin staining of cultured skin fibroblasts from the patient, to demonstrate free cholesterol accumulation in lysosomes secondary to impaired intracellular cholesterol transport.

Efficacy of miglustat in Niemann-Pick C disease: a single centre experience.

Miglustat Improves Purkinje Cell Survival and Alters Microglial Phenotype in Feline Niemann-Pick Disease Type C

Results suggest that prolonged Purkinje cell survival, reduced glycosphingolipid accumulation, and/or the modulation of microglial immunophenotype and function contribute to miglustat-induced neurological improvement in treated cats.

A new surrogate marker for CNS pathology in Niemann-Pick disease type C?

Long-Term Miglustat Therapy in Children With Niemann-Pick Disease Type C

Miglustat stabilized neurological disease progression in pediatric patients with Niemann-Pick disease type C, with comparable safety and tolerability to that observed in adults and juveniles.
...

References

SHOWING 1-10 OF 40 REFERENCES

Niemann-Pick disease type C: cataplexy and hypocretin in cerebrospinal fluid.

A Japanese patient with NPC caused by a homozygous c.2974 G > T mutation of the NPC1 gene, which predicts a glycine to tryptophan change at codon 992, is reported, confirming the association of reduced CSF hypocretin-1 levels with cataplexy in NPC.

Therapy of Niemann-Pick disease, type C.

A Riddle Wrapped in a Mystery: Understanding Niemann-Pick Disease, Type C

NPC is a model for inborn errors of metabolism whose gene product mediates molecular trafficking rather than catabolizing macromolecules, as in classic lipid storage diseases.

The natural history of Niemann–Pick disease type C in the UK

There is a clear need to develop a specific treatment for this progressively debilitating neurodegenerative disorder, and a review of NPC patients in the UK confirms the phenotypic variability of this inherited lipid storage disorder.

Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease

It has been shown that treatment with miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) improves key clinical features of type I Gaucher disease after 1 year of treatment and longer-term efficacy and safety data are reported.

Niemann-Pick C1 disease: the I1061T substitution is a frequent mutant allele in patients of Western European descent and correlates with a classic juvenile phenotype.

The I1061T mutation originated in Europe and the high frequency in northern Rio Grande Hispanics results from a founder effect, and testing for this mutation has important implications for genetic counseling of families affected by NPC.

Identification of HE1 as the second gene of Niemann-Pick C disease.

Treatment of NP-C2 fibroblasts with exogenous recombinant HE1 protein ameliorated lysosomal accumulation of low density lipoprotein-derived cholesterol.